| Stereochemistry | ACHIRAL |
| Molecular Formula | C21H16 |
| Molecular Weight | 268.3517 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C2CCC3=C2C(C=C1)=CC4=C3C=CC5=CC=CC=C45
InChI
InChIKey=PPQNQXQZIWHJRB-UHFFFAOYSA-N
InChI=1S/C21H16/c1-13-6-7-15-12-20-17-5-3-2-4-14(17)8-9-18(20)19-11-10-16(13)21(15)19/h2-9,12H,10-11H2,1H3
| Molecular Formula | C21H16 |
| Molecular Weight | 268.3517 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
3-Methylcholanthrene a compound, which can activate both aryl hydrocarbon receptor (AhR) and estrogen receptor alpha. It is used to induce fibrosarcomas and skin carcinomas in laboratory animals. The daily exposure to 3-methylcholanthrene induced changes in both gene expression and epigenomic remodeling, which had led to premature ovarian failure.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Sample Use Guides
in rats: daily intraperitoneally injected with 0.1 or 1 mg/kg. It induced changes in both gene expression and epigenomic remodeling, which may lead to premature ovarian failure.
Route of Administration:
Intraperitoneal
It was investigated the proliferation and angiogenesis of human umbilical vascular endothelial cells under the action of 3-methylcholanthrene (3-MC). 3-MC (concentration: 5 nM; 50 nM; 500 nM) suppressed DNA synthesis of human umbilical vascular endothelial cells as determined by [(3)H]thymidine incorporation in a concentration-dependent fashion and arrested cells at the G0/G1 phase of the cell cycle. Cell permeability, adhesion, and tube formation in human umbilical vascular endothelial cells exposed to 3-MC decreased in concentration-dependent manners.
